This site uses cookies. Some of these cookies are essential to the operation of the site, while others help to improve your experience by providing insights into how the site is being used. For more information, please see the ProZ.com privacy policy.
Cookie settings
Asked
Open questions
Answered
Asked | Open questions | Answered
Date Pair Term Level Status Answers (undeclined) Gloss
Jul 29 '10 eng>rus Project: EP 2006 pro closed 3 no
Jul 29 '10 eng>rus manufacturing records/ analytical records pro closed 2 no
Jul 29 '10 eng>rus residual DNA pro closed 1 no
Jul 29 '10 eng>rus identity CZE pro closed 1 ok
Jul 29 '10 eng>rus quality assurance BPO pro open 3 no
Jul 25 '10 eng>rus Origin synthetic pro closed 2 no
Jul 25 '10 eng>rus Shipment under ice pro closed 3 no
Jul 24 '10 eng>rus assigned content pro closed 4 no
Jul 24 '10 eng>rus Dispatching conditions pro closed 3 no
Jul 17 '10 eng>rus IMS pro closed 2 no
Jul 17 '10 eng>rus more challenging to test pro closed 2 no
Jul 16 '10 eng>rus relative statistical control. pro closed 3 no
Jul 14 '10 eng>rus Harmful. Mild irritant pro closed 1 ok
Jul 13 '10 eng>rus PSO Gomme Xanthane JBZ pro closed 1 no
Jul 13 '10 eng>rus initial qualification pro closed 2 no
Jul 13 '10 eng>rus Use at potency: 99.8% as is pro closed 1 no
Jul 13 '10 eng>rus associate director X global quality reference standarts pro closed 2 no
Jul 6 '10 eng>rus truncated to zero pro closed 2 no
Jul 5 '10 eng>rus overall mean half-life pro closed 2 no
Jul 5 '10 eng>rus Trial Outline pro closed 5 no
Jul 5 '10 eng>rus Competitive enrolment pro closed 4 no
Jul 5 '10 eng>rus department of Cell and Antibody Analysis pro closed 3 no
Jul 4 '10 eng>rus (designated) current process pro closed 2 no
Jul 4 '10 eng>rus Department Medical & Science, Haemostasis pro closed 2 no
Jul 4 '10 eng>rus GlycoPEGylation pro closed 3 no
Jul 3 '10 eng>rus on an exploratory basis pro closed 2 ok
Jul 3 '10 eng>rus presented by treatment in descriptive summaries/summarised by treatmеnt pro closed 2 ok
Jun 26 '10 eng>rus trial subject’s female pregnant PARTNER pro closed 3 no
May 31 '10 eng>rus Patient-use Stability Conclusion pro closed 1 no
May 31 '10 eng>rus patient-use situation was simulated pro closed 2 no
May 30 '10 eng>rus plunger rod is mounted pro closed 2 no
May 30 '10 eng>rus tip cap pro closed 1 no
May 29 '10 eng>rus main/secondary drying process pro closed 2 no
May 26 '10 eng>rus Integrated Overview of the Non-clinical Testing Strategy pro closed 2 ok
May 25 '10 eng>rus two different occasions pro closed 2 no
May 25 '10 eng>rus without obvious trend or pattern pro closed 3 no
May 24 '10 eng>rus completed Phase 3 formulation pro closed 1 ok
May 24 '10 eng>rus provides a statistically significantly greater improvement pro closed 3 no
May 23 '10 eng>rus summarised by shift tables pro closed 1 no
May 23 '10 eng>rus reduced by a maximum of 0.50 mg in steps of 0.25 mg pro closed 1 no
May 23 '10 eng>rus unacceptable dose level pro closed 2 no
May 23 '10 eng>rus Consolidated Guideline pro closed 2 ok
May 22 '10 eng>rus by specifying contrasts in group and visit effects pro closed 3 no
May 22 '10 eng>rus prospective food consumption pro closed 2 ok
May 21 '10 eng>rus Note of Clarification on Paragraph pro closed 2 no
May 21 '10 eng>rus Sensations of appetite pro closed 2 no
May 21 '10 eng>rus signatory investigator pro closed 2 no
May 21 '10 eng>rus injection medium pro closed 2 no
May 21 '10 eng>rus Reference Therapy pro closed 2 no
May 17 '10 eng>rus complete nasal examination pro closed 2 ok
Asked | Open questions | Answered